China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital. The collaboration aims to integrate Insilico’s cutting-edge generative AI drug discovery platform Pharma AI with Tenacia’s proprietary data assets to develop small molecule inhibitors with the potential to penetrate the blood-brain barrier (BBB).
Partnership Focus
The partnership will focus on the early research and development of novel CNS therapies. By combining Insilico’s AI-powered drug discovery capabilities with Tenacia’s expertise in CNS disorders, the companies aim to accelerate the development of innovative treatments for conditions such as Alzheimer’s and Parkinson’s disease.-Fineline Info & Tech
Leave a Reply